Claritev (NYSE:CTEV) SVP Tiffani Misencik Sells 8,850 Shares

Claritev (NYSE:CTEV) SVP Tiffani Misencik sold 8,850 shares of the stock in a transaction that occurred on Friday, August 14th. The shares were sold at an average price of $40.07, for a total transaction of $354,619.50. Following the sale, the senior vice president directly owned 123,723 shares of the company’s stock, valued at $4,957,580.61. The trade was a 6.68% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

Claritev Stock Up 0.2%

Shares of CTEV opened at $35.42 on Wednesday. The company has a 50 day moving average of $30.15 and a two-hundred day moving average of $24.14. Claritev has a twelve month low of $11.50 and a twelve month high of $74.07. The company has a market cap of $600.37 million, a price-to-earnings ratio of -2.08 and a beta of 0.74.

Claritev (NYSE:CTEV) last issued its quarterly earnings results on Friday, August 7th. The company reported $1.41 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($4.10) by $5.51. The business had revenue of $257.48 million for the quarter. On average, sell-side analysts expect that Claritev will post -15.08 EPS for the current year.

Institutional Trading of Claritev

Several large investors have recently added to or reduced their stakes in the company. State of Wyoming purchased a new position in shares of Claritev in the fourth quarter worth about $25,000. Public Employees Retirement System of Ohio purchased a new stake in Claritev in the first quarter valued at approximately $38,000. Ameritas Investment Partners Inc. purchased a new stake in Claritev in the third quarter valued at approximately $42,000. Legal & General Group Plc acquired a new position in Claritev in the 3rd quarter worth approximately $45,000. Finally, Los Angeles Capital Management LLC acquired a new position in Claritev in the 4th quarter worth approximately $45,000. Hedge funds and other institutional investors own 87.15% of the company’s stock.

Analyst Ratings Changes

CTEV has been the subject of a number of research analyst reports. Barclays assumed coverage on Claritev in a research note on Friday, April 24th. They issued an “overweight” rating and a $28.00 price target for the company. Weiss Ratings restated a “sell (d-)” rating on shares of Claritev in a report on Wednesday, June 24th. Piper Sandler reaffirmed an “overweight” rating and issued a $73.00 price objective on shares of Claritev in a research report on Wednesday, August 12th. Canaccord Genuity Group lifted their target price on shares of Claritev from $37.00 to $43.00 and gave the stock a “buy” rating in a research note on Monday, August 10th. Finally, Wells Fargo & Company boosted their target price on shares of Claritev from $22.00 to $30.00 and gave the stock an “equal weight” rating in a research report on Wednesday, August 12th. Six equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $42.83.

Claritev Company Profile

Claritev is a healthcare technology, data and insights company focused on improving affordability,  transparency and quality. Led by deeply experienced associates, data scientists, and innovators, Claritev provides tech-enabled solutions and services fueled by multiple data sources from over 40 years of claims repricing. Claritev utilizes world-class technology and AI solutions to power a robust enterprise platform that delivers meaningful insights to drive affordability in healthcare, brings price transparency and optimizes networks and benefits design.